Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection
Open Access
- 5 July 2013
- journal article
- Published by Springer Nature in Parasites & Vectors
- Vol. 6 (1) , 199
Abstract
Hepatic schistosomiasis is considered to be one of the most prevalent forms of chronic liver disease in the world due to its complication of liver fibrosis. The demonstration of the pro-fibrogenic role of angiotensin (Ang) II in chronic liver disease brought up the idea that anti-Ang II agents may be effective in improving hepatic fibrosis by either blocking Ang II type 1 (AT1) receptors or inhibiting the angiotensin converting enzyme. Peroxisome proliferator-activated receptors gamma (PPARγ) activation has been also shown to inhibit hepatic stellate cell activation and progression of fibrosis. The present study has aimed at testing the anti-fibrogenic effects of telmisartan; an AT1 receptor blocker and a PPARγ partial agonist, alone or combined with praziquantel (PZQ) on Schistosoma mansoni-induced liver fibrosis in mice.Keywords
This publication has 47 references indexed in Scilit:
- Schistosoma haematobium infections among schoolchildren in central Sudan one year after treatment with praziquantelParasites & Vectors, 2012
- Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosisParasites & Vectors, 2012
- Neglected Tropical Diseases and the Millennium Development Goals-why the "other diseases" matter: reality versus rhetoricParasites & Vectors, 2011
- New Insight into the Antifibrotic Effects of Praziquantel on Mice in Infection with Schistosoma japonicumPLOS ONE, 2011
- Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?European Journal of Pharmacology, 2009
- Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicumWorld Journal of Gastroenterology, 2008
- Pharmacodynamics of pentoxifylline and/or praziquantel in murine schistosomiasis mansoniAPMIS, 2007
- Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ-inducing propertyMedical Hypotheses, 2005
- An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cellsBritish Journal of Pharmacology, 2003
- Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-α and TGF-β1Journal of Hepatology, 1999